NexHA™ (hyaluronate sodium) Injectable Solution now available in a 3-vial box

NexHA™ (hyaluronate sodium) Injectable Solution now available in a 3-vial box

FORT WORTH, TEXAS (July 1, 2026) – Vetoquinol USA, Inc., is now offering NexHA™ (hyaluronate sodium) Injectable Solution in a three-vial box. Previously, the product was available in a 12-vial box.

The company made the change after discussions with veterinarians and horse owners. The three-vial box makes ordering and inventory management simpler for clinics with a full protocol for a single horse.

Treatment with NexHA may be repeated at weekly intervals for a total of three treatments. Each vial contains 4 mL (40 mg) of solution for intravenous injection.

Intravenous administration of hyaluronate sodium is FDA-approved to help alleviate signs of lameness associated with equine osteoarthritis. NexHA can be used as part of veterinary management of equine joint conditions, with treatment decisions, including use with other therapies, made by a veterinarian.

Generic products, like NexHA, are produced under the same standards and have demonstrated bioequivalence to the brand-name product.¹ Using affordable generics allows owners to invest in other important veterinary services.

The 12-vial box will continue to be sold until inventory is depleted. NexHA is a prescription-only product. Veterinarians can request NexHA from their Vetoquinol Territory Manager or preferred distributor representative.

NexHA™ (hyaluronate sodium) Injectable Solution is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.

IMPORTANT SAFETY INFORMATION: 
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For use only in horses. Do not use in horses intended for human consumption.

NexHA™ (hyaluronate sodium) Injectable Solution 4 mL is approved only for intravenous use. The safety of NexHA™ (hyaluronate sodium) Injectable Solution has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares. Not for use in humans. Keep this and all other drugs out of reach of children. Post-Approval Experience: While all adverse reactions are not reported, the following adverse reactions are based on voluntary post-approval reporting for hyaluronate sodium injectable solution: Occasional depression, lethargy and fever. For full prescribing information, visit www.vetoquinolusa.com/nexha-info.

Company Contact Information
Consumers:
Vetoquinol USA Account Services
800-267-5707
customerserviceusa@vetoquinol.com
 

For media requests:

usa_news@vetoquinol.com

About Vetoquinol USA

Headquartered in Fort Worth, Texas, Vetoquinol USA, Inc. is owned by Vetoquinol S.A., an independent, family-owned French pharmaceutical company founded in 1933. Dedicated exclusively to animal health, Vetoquinol USA is focused on the development, production, and marketing of AAFCO, NASC, EPA, and FDA-regulated pharmaceutical, nutritional, and dermatological products for small and large animals.

1. U.S. Food & Drug Administration. (2025 Aug 27). Abbreviated New Animal Drug Applications. https://www.fda.gov/animal-veterinary/development-approval-process/abbr…. Accessed June 10, 2026

©2026 VETOQUINOL USA, Inc. VETOQUINOL and NexHA are trademarks of VETOQUINOL. Other brands are trademarks of their respective owners. NEX-26-00007